Présentation de l'entreprise
Aclaris Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity focused on the discovery and development of novel molecule product candidates designed to treat immuno-inflammatory diseases within the United States. The company functions within the healthcare sector, specifically targeting the biotechnology industry, which is characterized by high research and development costs and long product development cycles before market entry. With a market capitalization of $478.29M, an annual revenue of $7.83M, and a workforce of 69 employees, the company maintains a relatively small operational footprint typical of entities in the early phases of commercialization. These valuation and revenue figures indicate that the company is currently in a growth-oriented stage where market capitalization is driven primarily by asset potential and pipeline value rather than established cash flow generation. The disparity between the market cap and the modest revenue base suggests that the majority of the company's value is attributed to future expectations regarding its product pipeline, including candidates like Bosakitug (ATI-045), rather than current profitability. This structural characteristic is common in biotechnology firms that require significant capital investment to advance clinical trials before achieving substantial commercial sales.
Santé financière
The company reported revenue of $7.83M over the trailing twelve months, while net income stood at -$64,923,000 and EBITDA at -$74,035,000, highlighting a significant divergence between top-line activity and bottom-line performance. The substantial gap between the relatively low revenue of $7.83M and the net loss of -$64,923,000 reveals an extremely high cost structure where operating expenses, likely dominated by clinical trial costs and R&D expenditures, far exceed current sales. Free cash flow was recorded at -$30,631,876, indicating that the company is consuming cash to fund its operations and development activities, which limits immediate financial flexibility without external financing. Despite this cash burn, the balance sheet holds $90.75M in cash against a debt level of $2.12M, providing a substantial liquidity buffer to support ongoing research and development efforts. The debt-to-equity ratio of 2.05 suggests a leveraged capital structure, yet the absolute debt amount remains low relative to the cash on hand, mitigating immediate refinancing risks. The current ratio of 3.36 indicates strong short-term liquidity, as the company possesses more than three times the current assets necessary to cover its short-term liabilities. Return on Equity is -50.2% and Return on Assets is -24.3%, metrics that reflect the dilutive impact of losses on shareholder value and the efficiency of asset utilization during this pre-revenue or early-revenue phase of the business lifecycle.
Évaluation de la valorisation
Trailing twelve-month P/E ratio is N/A due to the lack of positive net income, while the forward P/E stands at -5.27, implying that the market currently prices in future earnings growth that has not yet materialized in reported results. The price-to-book ratio is 4.62, indicating that the market values the company at more than four and a half times its book value, which reflects a significant premium assigned to the intangible assets and potential of the biotechnology pipeline rather than tangible net worth. The price-to-sales ratio is exceptionally high at 61.12, and the EV/EBITDA is -5.24, suggesting that traditional valuation multiples are not applicable and that the company is being valued based on non-GAAP measures or forward-looking projections of pipeline success. The stock has traded within a range with a 52-week high of $4.89 and a 52-week low of $1.05, meaning the current share price sits somewhere within this volatility band subject to market sentiment regarding the company's clinical milestones. With a beta of 0.68, the stock exhibits lower volatility relative to the broader market, moving at roughly two-thirds the intensity of the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is -85.9%, while earnings growth is N/A due to the company's negative earnings position, illustrating that the company is currently shrinking in terms of sales volume rather than expanding its top line. The negative revenue growth rate combined with N/A earnings growth indicates that the company is likely in a transition period where sales may be transitioning from previous products or clinical trials are delaying new product commercialization. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which is consistent with the practice of reinvesting all available capital and raising new funds to finance expensive clinical trials rather than distributing income to shareholders. The overall growth and income profile is defined by significant revenue contraction and a complete absence of dividend income, reflecting a classic high-risk biotechnology business model where value is derived solely from the potential success of future product candidates rather than current financial performance or shareholder distributions.